This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer
Evidence-Based Benefits
Cognitive function — pregnenolone sulfate enhanced memory in rodent models and showed preliminary improvements in cognitive scores in schizophrenia patients (Marx et al., 2009)
Mood support — a pilot RCT in bipolar depression showed improvements in depressive symptoms at 500mg daily (Brown et al., 2014)
Hormone restoration — oral supplementation raises serum pregnenolone and downstream metabolites including DHEA and progesterone
Neuroprotection — pregnenolone sulfate modulates NMDA and GABA-A receptors as an endogenous neurosteroid
What the Research Says
Pregnenolone is a neurosteroid that has demonstrated potential in specific psychiatric applications. Marx et al. (2009) conducted a randomized, placebo-controlled trial involving 21 schizophrenia patients and found that pregnenolone significantly improved negative symptoms, as measured by the SANS scores. Similarly, Brown et al. (2014) reported that in a double-blind, placebo-controlled trial with 73 participants, pregnenolone demonstrated significant antidepressant effects in individuals with bipolar disorder at higher doses.
The modulation of NMDA and GABA-A receptors by pregnenolone is well-documented in preclinical studies. However, large-scale randomized controlled trials (RCTs) evaluating its efficacy for common supplementation indications, such as anti-aging or cognitive enhancement in healthy adults, remain scarce. A meta-analysis by Li et al. (2026) of 74 RCTs involving 5,484 participants highlighted that while several anti-inflammatory drugs showed initial benefits for schizophrenia symptoms, these findings were tempered by high heterogeneity and significant publication bias, limiting their clinical significance.
Additionally, Stomati et al. (2000) conducted a randomized controlled trial with 36 postmenopausal women (ages 50-65) to assess the effects of DHEA supplementation over six months. The study found that daily administration of 50 mg DHEA increased levels of several hormones, including DHEA, DHEAS, androgens, estradiol, and beta-endorphin, while decreasing SHBG and gonadotropins. Although this study does not directly address pregnenolone's effects, it underscores the broader hormonal influences of neurosteroids.
Overall, while pregnenolone has shown potential in specific psychiatric contexts, further research is needed to establish its efficacy and safety for other indications.
RCTMarx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, Shampine LJ (2009). Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology. DOIPubMed
RCTBrown ES, Park J, Marx CE, Hynan LS, Gardner C, Davila D, Nakamura A, Sunderajan P, Lo A, Holmes T (2014). A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology. DOIPubMed
Meta-analysisLi H, Shen H, Duan X, Guo M, et al. (2026). Efficacy and safety of anti-inflammatory drug-assisted treatment of symptoms in patients with schizophrenia: a meta-analysis.. BMC psychiatry. DOIPubMed
RCTStomati M, Monteleone P, Casarosa E, Quirici B, et al. (2000). Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. DOIPubMed
